-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Guolong Pharmaceutical of Shijiazhuang Sihua Pharmaceutical Group Awarded the Shijiazhuang Municipal Government Quality Award – Organizational Category
Category:
发布时间：2025-06-19
【概要描述】
Recently, the People’s Government of Shijiazhuang City officially issued the “Decision on Awarding the Sixth Shijiazhuang Municipal Government Quality Award,” under which Hebei Guolong Pharmaceutical Co., Ltd. of Shijiazhuang Sihua Pharmaceutical Group was presented with the Organizational Award for its outstanding product quality, innovative management philosophy, and comprehensive management system. This honor represents a high level of recognition and full affirmation of Guolong Pharmaceutical’s exceptional performance in the field of quality management.
Recently, the People’s Government of Shijiazhuang City officially issued the “Decision on Awarding the Sixth Shijiazhuang Municipal Government Quality Award,” under which Hebei Guolong Pharmaceutical Co., Ltd. of Shijiazhuang Sihua Pharmaceutical Group was presented with the Organizational Award for its outstanding product quality, innovative management philosophy, and comprehensive management system. This honor represents a high level of recognition and full affirmation of Guolong Pharmaceutical’s exceptional performance in the field of quality management.
According to reports, the Shijiazhuang Municipal Government Quality Award was established in 2012. Hosted by the Municipal People’s Government and organized by the Municipal Administration for Market Regulation, it is the highest honor conferred by the city of Shijiazhuang in the field of quality management. The award is primarily presented to organizations that demonstrate outstanding quality management practices, strong capabilities in independent innovation, high brand recognition, and significant economic and social benefits, as well as to individuals who have achieved remarkable results in quality-related work and made outstanding contributions to building Shijiazhuang into a city renowned for its quality. This year, a total of nine organizations were awarded the Organizational Prize, and nine individuals were awarded the Individual Prize.
As one of the core enterprises under Shijiazhuang Sihua Pharmaceutical Group, Guolong Pharmaceutical has in recent years kept pace with industry development by actively implementing an integrated “API-plus-formulation” development strategy. The company focuses on the R&D and production of specialty APIs and innovative APIs, leveraging collaboration among industry, academia, research institutions, and end-users. Guided by a product-development positioning centered on refinement, product serialization, and specialization, Guolong Pharmaceutical is vigorously building its technological platforms and establishing an enterprise-driven innovation system with new-product development at its core. Through targeted technological breakthroughs in key common technologies—such as API crystallization, bioenzyme catalysis, and the preparation of polymeric APIs—Guolong Pharmaceutical has successively obtained approval for 33 new products and 22 invention patents, and has participated in the formulation of 22 national standards, thereby establishing a new model of product-iteration development characterized by “a batch of R&D and innovation, a batch of technology transfer, and a batch of pipeline reserves.”
In the realm of quality management, Guolong Pharmaceutical has consistently adhered to the development philosophy of “winning through quality.” By adopting and implementing the Excellence Performance Model, the company has continuously optimized its management system and comprehensively advanced the standardization of its entire value chain—covering production management, testing procedures, manufacturing operations, talent development, and sales and service—thereby enhancing product quality and brand influence. Its key active pharmaceutical ingredients, including hydroxyethyl starch derivatives, azithromycin, arbidol hydrochloride, and moxifloxacin hydrochloride, are widely favored by the market, establishing Guolong Pharmaceutical as a stable supplier and strategic partner to numerous renowned domestic and international formulation manufacturers. The company has successively been recognized with prestigious titles such as Hebei Province’s Specialized, Sophisticated, Distinctive, and Innovative SME, Provincial Demonstration Enterprise for Specialization and Sophistication, and Provincial Benchmark Enterprise for Quality in the Industrial Sector.
“Winning the Municipal Government Quality Award—Organization Category is not only a recognition of Guolong Pharmaceutical’s past efforts but also a powerful incentive for our future development,” said Li Zhihui, Chairman of Guolong Pharmaceutical. He pledged that the company will steadfastly implement its quality-driven corporate strategy, remain customer-centric, strengthen its quality foundation, refine its quality management model, ensure the coordinated development of quality management and technological innovation, cultivate a strong awareness of quality and excellence, strive with determination to overcome challenges, and contribute even more to the high-quality development of Shijiazhuang’s biopharmaceutical industry.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091